PEGASUS – TIMI 54 was a randomized, double-blind, placebo-controlled trial to assess the prevention of thrombotic events with ticagrelor on a background of aspirin therapy in patients with history of myocardial infarction.
MAIN RESULTS:
Long-term use of ticagrelor in patients with prior myocardial infarction

N Engl J Med. 2015 May 7;372(19):1791-800.
PRESENTATIONS
Main Results (Sabatine, ACC 2015)
PEGASUS Renal dysfunction (ESC 15)
PEGASUS-TIMI 54 PCI Subgroup 2015
PEGASUS-TIMI 54 P2Y12 Inhibitor Withdrawal 2015
PEGASUS-TIMI 54 Diabetes Subgroup (Bhatt, ACC 2016)
PEGASUS-TIMI 54 PAD Subgroup 2016PEGASUS Total events (AHA)
Caffeine (Furtado, AHA 2018)
No PCI (Furtado, AHA 2018)
hsTn (Marston, AHA 2018)
PEGASUS TMAO (Gencer, AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease (Garfinkel, AHA 2021)
A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease (Patel, AHA 2021)
Lipoprotein(a), Cardiovascular Events, and Benefit of P2Y12 Inhibition-Insights from the PEGASUS-TIMI 54 Trial (Patel, ESC 2022)
Development of a Novel Polygenic Risk Score to Predict Risk of Aortic Stenosis Events (Small, AHA 2022)
Lipoprotein(a) and the risk of Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease (Bonaca, ESC 2023)
Performance of a Polygenic Risk Score for CAD Across the Spectrum of ASCVD-An Analysis of 60k Patients from 6 TIMI Randomized Trials (Zimerman, AHA 2023)
OTHER PUBLICATIONS